The INSY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the INSY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The INSY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View INSY Detailed Price Forecast - CNN Money||View INSY Detailed Summary - Google Finance|
|View INSY Detailed Summary - Yahoo! Finance||View INSY Stock Research & Analysis - Zacks.com|
|View INSY Trends & Analysis - Trade-Ideas||View INSY Major Holders - Barrons|
|View INSY Call Transcripts - NASDAQ||View INSY Breaking News & Analysis - Seeking Alpha|
|View INSY Annual Report - CompanySpotlight.com||View INSY OTC Short Report - OTCShortReport.com|
|View INSY Fundamentals - TradeKing||View INSY SEC Filings - Bar Chart|
|View Historical Prices for INSY - The WSJ||View Performance/Total Return for INSY - Morningstar|
|View the Analyst Estimates for INSY - MarketWatch||View the Earnings History for INSY - CNBC|
|View the INSY Earnings - StockMarketWatch||View INSY Buy or Sell Recommendations - MacroAxis|
|View the INSY Bullish Patterns - American Bulls||View INSY Short Pain Metrics - ShortPainBot.com|
|View INSY Stock Mentions - StockTwits||View INSY Stock Mentions - PennyStockTweets|
|View INSY Stock Mentions - Twitter||View INSY Investment Forum News - Investor Hub|
|View INSY Stock Mentions - Yahoo! Message Board||View INSY Stock Mentions - Seeking Alpha|
|View Insider Transactions for INSY - SECform4.com||View Insider Transactions for INSY - Insider Cow|
|View INSY Major Holdings Summary - CNBC||View Insider Disclosure for INSY - OTC Markets|
|View Insider Transactions for INSY - Yahoo! Finance||View Institutional Holdings for INSY - NASDAQ|
|View INSY Stock Insight & Charts - FinViz.com||View INSY Investment Charts - StockCharts.com|
|View INSY Stock Overview & Charts - BarChart||View INSY User Generated Charts - Trading View|
INSYS Therapeutics, Inc. (OTCMKTS:INSYQ), announced today that its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational, proprietary naloxone nasal spray for the emergency treatment of known or suspected opioid overdose in both adult and pediatric patients has been accepted for filing. INSYS’ naloxone nasal spray is a single unit dose spray device that delivers 8mg naloxone dose. “The FDA’s acceptance of the NDA for INSYS’ proprietary formulation of a naloxone nasal spray is an important milestone in battling the U.S. opioid epidemic,” said Dr. Venkat Goskonda, chief scientific officer at INSYS Therapeutics. INSYS Therapeutics is a specialty pharmaceutical company using proprietary technology and capabilities to develop and commercialize innovative pharmaceutical products intended to address unmet medical needs and the clinical shortcomings of existing commercial products.
Opinion: Medical Marijuana Is a Terrible Investment
Posted on Thursday June 20, 2019
Medical marijuana drug developers are often smothered in hype and rarely deliver any reward.
Insys Therapeutics Bankruptcy: INSY Stock Soars on Latest News
Posted on Wednesday June 12, 2019
Insys Therapeutics bankruptcy news for Wednesday has INSY stock heading higher.Source: Insys TherapeuticsInsys Therapeutics (NASDAQ:INSY) notes that it now has approval from the U.S. Bankruptcy Court for the District of Delaware for its First Day motions. It received this approval on Tuesday, but only just announced the news today.This approval will allow the company to move forward with its Insys Therapeutics bankruptcy plans. This marks a move in the right direction for the company as it looks to use the bankruptcy protection to cover its legacy legal liabilities.InvestorPlace - Stock Market News, Stock Advice & Trading TipsWith the First Day motions approval, Insys Therapeutics will be able to continue operations throughout the bankruptcy process. This includes it continuing to pay employees for their work. It will also let the company keep paying its vendors."This is an important step forward in our court-supervised process, which is intended to fairly and transparently address the Company's legacy legal liabilities," Andrew Long, CEO of Insys Therapeutics, said in a statement. "I would like to thank our team for their continued hard work and dedication as we move forward with our asset sale process." * 7 Stocks to Buy for the Coming Recession The Insys Therapeutics bankruptcy won't just have the company selling off some of its assets to cover its legal costs. Instead, it will be selling "substantially all" of its assets during the process.INSY stock was up 189% as of noon Wednesday, but is down 96% since the start of the year. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy for the Coming Recession * 10 Smart Dividend Stocks for the Rest of the Year * 5 Tech Stocks That Are Far Too Risky Right Now As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Insys Therapeutics Bankruptcy: INSY Stock Soars on Latest News appeared first on InvestorPlace.
Zynerba Up on Second Patent for Cannabidiol Candidate in 2019
Posted on Wednesday June 12, 2019
Zynerba (ZYNE) gets a new U.S. patent covering methods of treating autism spectrum disorder with cannabidiol, a key compound of its lead pipeline candidate, Zygel.